TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
18.61
+1.31 (+7.57%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close17.30
Open17.81
Bid0.00 x 0
Ask0.00 x 0
Day's Range17.50 - 18.70
52 Week Range10.85 - 38.31
Volume66,141,613
Avg. Volume25,696,853
Market Cap18.908B
Beta0.63
PE Ratio (TTM)N/A
EPS (TTM)-5.87
Earnings DateN/A
Forward Dividend & Yield0.34 (2.17%)
Ex-Dividend Date2017-11-27
1y Target Est15.11
Trade prices are not sourced from all markets
  • Reuters5 hours ago

    Strike over Teva Pharm job cuts briefly shuts down Israel

    Israel's main public-sector labour union staged a half-day strike on Sunday, closing the airport, stock exchange, banks and all government ministries to protest at mass layoffs planned by Teva Pharmaceutical Industries. Debt-ridden Teva, one of Israel's largest companies and the world's largest generics drugmaker, said last week it would cut its global workforce by more than a quarter, or 14,000 jobs. Some 1,700 jobs will be cut and a manufacturing site will be closed in Israel.

  • Reuters6 hours ago

    Strike over Teva Pharm job cuts briefly shuts down Israel

    Israel's main public-sector labour union staged a half-day strike on Sunday, closing the airport, stock exchange, banks and all government ministries to protest at mass layoffs planned by Teva Pharmaceutical Industries. Debt-ridden Teva, one of Israel's largest companies and the world's largest generics drugmaker, said last week it would cut its global workforce by more than a quarter, or 14,000 jobs. Some 1,700 jobs will be cut and a manufacturing site will be closed in Israel.

  • Israeli workers strike nationwide to protest Teva layoffs
    Associated Press7 hours ago

    Israeli workers strike nationwide to protest Teva layoffs

    JERUSALEM (AP) — Israel's national trade union on Sunday held a half-day nationwide strike to protest generic drugmaker Teva's decision to lay off a quarter of its workforce, snarling traffic and shuttering key services across the country.

  • Strike Over Teva Firings Shuts Israel Bourse, Banks, Airport
    Bloomberg12 hours ago

    Strike Over Teva Firings Shuts Israel Bourse, Banks, Airport

    Striking workers idled Israel’s international airport, government offices, banks and stock market for half a day, pressing to scale back Teva Pharmaceutical Industries Ltd.’s plan to fire 25 percent of ...

  • TheStreet.com2 days ago

    Teva Shares Rocket Higher Erasing Loses; CSX Savior Takes Leave -- ICYMI

    Here's what you need to know now for Friday, Dec. 15.

  • TheStreet.com2 days ago

    Teva Pharmaceutical 'Turned a Corner' This Week: Goldman Sachs

    The Petach Tikva, Israel-based drugmaker on Dec. 15 launched generic Viread a day after announcing plans to cut 14,000 jobs globally over the next two years as part of restructuring efforts. Here come ...

  • Can Teva Jump-Start Its Restructuring By Swiping Some Of Gilead's Sales?
    Investor's Business Daily2 days ago

    Can Teva Jump-Start Its Restructuring By Swiping Some Of Gilead's Sales?

    Teva continued its two-day upswing Friday after announcing the launch of a generic version of a drug from Gilead, a day after the drugmaker unveiled a massive cost-cutting plan.

  • SmarterAnalyst2 days ago

    Teva Pharmaceutical Industries Ltd (TEVA): Thanks for the Cuts But Where Is the Revenue Guidance?

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares have gained almost 15% in value since yesterday after new Danish CEO Kare Schultz's first conference call, where the recovering Israeli pharma giant's leadership unveiled cost cutting plans that outclassed Street-wide expectations. For Koffler, "the punch line" boils down to the giant's strategy to scale back $3 billion in expenses along with a reduction of a quarter of its workforce by 2019 from a projected cost base of $16.1 billion this year. The goal is for over half of this cost cutting, or past $1.5 billion, to be seen through next year.

  • Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
    Investor's Business Daily2 days ago

    Beware: Price Wars For Big Pharma, Biotech Companies On Horizon

    The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.

  • Benzinga2 days ago

    Credit Suisse Upgrades Teva After Job Cuts Announced

    Impressed with the turnaround initiatives at Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ), an analyst at Credit Suisse upgraded the company's  shares . The Analyst Credit Suisse analyst Vamil ...

  • Investopedia2 days ago

    Teva Stock Breaks Out, but Will the Rally Last?

    Teva shares are soaring after restructuring plans, but traders will be watching these key levels.

  • Barrons.com2 days ago

    Teva or Neva: Will the Turnaround Plan Work?

    Shares of Teva Pharmaceuticals (TEVA) are higher on Friday, following a pair of upgrades. The moves come after Teva announced a restructuring plan on Thursday, following the stock's nearly 50% slump since the start of the year. Credit Suisse's Vamil Divan upgraded the stock to Neutral, writing that the company's turnaround looks positive and management is making the right moves--although execution is key.

  • Benzinga2 days ago

    Goldman Sachs: Now Is The Time To Get In On Teva's Turnaround

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA ) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. ...

  • SmarterAnalyst2 days ago

    Teva Pharmaceutical Launches First Generic Formulation of Gilead’s Blockbuster Antiretroviral Truvada

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced this morning the exclusive US launch of Viread®1 (tenofovir disoproxil fumarate) tablets 300 mg, a generic version of Gilead Sciences' (NASDAQ:GILD) Viread tablets. Truvada was initially approved by FDA in 2004 to treat HIV in combination with other antiretroviral drugs, and later gained approval as the first drug to prevent sexually transmitted HIV-1 infection in uninfected adults in 2012. Viread®1 received an FDA approval for its Abbreviated New Drug Application (ANDA) in June, granting Teva the right to produce generic Truvada for the combination tablet’s use as a component of an HIV treatment regimen and as pre-exposure prophylaxis (PrEP).

  • MarketWatch2 days ago

    Teva’s new plan is to raise drug prices, but it won’t be easy

    Generic drug prices have been declining all year, posing a crisis for the industry and prompting the very cost-cutting that Teva just announced.

  • MarketWatch2 days ago

    Teva to lay off 14,000 workers in bid for survival — but some are skeptical

    The restructuring is supposed to help turn around the beleaguered company, but could actually hurt it, some Wall Street analysts said.

  • MarketWatch2 days ago

    Teva to launch generic version of Gilead's Viread in the U.S.

    Shares of Teva Pharmaceutical Industries Ltd. rallied 3.5% in premarket trade Friday, after the drug maker announced the exclusive launch of generic Viread 1 tablets (300 milligrams) in the U.S. The rally ...

  • Business Wire2 days ago

    Teva Announces Exclusive Launch of Generic Viread® in the United States

    Teva Pharmaceutical Industries Ltd., today announced the exclusive launch of generic Viread®1 tablets 300 mg in the U.S.

  • ACCESSWIRE2 days ago

    Today’s Research Reports on Trending Tickers: GW Pharmaceuticals and Teva Pharmaceutical Industries

    NEW YORK, NY / ACCESSWIRE / December 15, 2017 / Progress of the recent tax bill hit a snag on Thursday as two GOP Senators raised some concerns. All sectors closed down on Thursday dragging markets lower, ...

  • CNBC2 days ago

    Teva Pharmaceutical shares jump after Goldman upgrades embattled drugmaker, predicts turnaround

    Goldman Sachs raises its rating to buy for the generic drugmaker, citing Teva's aggressive cost-cutting targets for the next two years.

  • Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook
    Zacks2 days ago

    Pharma Stock Roundup: Teva Announces Major Job Cuts, Lilly Provides 2018 Outlook

    This week's pharma sector highlights include ASH data, Teva's restructuring announcement and Lilly's (LLY) 2018 outlook.

  • Stocks Skittish on Tax Worries
    InvestorPlace2 days ago

    Stocks Skittish on Tax Worries

    U.S. equities fell on Thursday amid doubts over the fate of the GOP’s tax cut plans. The doubt hit investors after a number of Republican senators expressed reservations about the amount of the child tax credit. In the end, the Dow Jones Industrial Average lost 0.3%, the S&P 500 lost 0.4%, the Nasdaq Composite lost 0.3% and the Russell 2000 lost 1.2%.

  • 24/7 Wall St.2 days ago

    Teva Pharmaceuticals: Happy Holidays, You’re Fired

    Another company has decided that the best time to fire a large number of people is just before the holidays.

  • The Wall Street Journal3 days ago

    [$$] Teva Pharmaceutical to Cut 14,000 Jobs

    Teva Pharmaceutical is cutting more than 25% of its workforce and suspending its dividend as it works to cut costs and pay down debt.

  • American City Business Journals3 days ago

    Massive Teva layoffs leave OP operation's future unknown

    Teva Pharmaceutical Industries Ltd. announced plans to cut its global workforce and consolidate its U.S. offices, but the Israel-based pharmaceutical company (TEVA) has not yet announced plans for its Overland Park headquarters, which hosts 388 employees. Teva also will consolidate its seven U.S. locations into one main campus, but that location has yet to be determined, Senior Director of Communications Kaelan Hollon wrote in an email. Teva's North American headquarters are currently located in North Wales, Pa., but the company did not state whether that could change, the Philadelphia Business Journal reported .